Deeptech health automation startup Morphle Labs has raised $5 million in its Series A round led by Inflexor Ventures.
The company will use the new funds to support its global expansion plans, increase manufacturing capacity for its systems RoboTome and MorphoLens, secure regulatory approvals across multiple regions, and continue technology development across hardware, optics and imaging intelligence.
Founded in 2017 by Rohit Hiwale, Morphle Labs started in the tissue-diagnostics space with a focus on automated histopathology, a process that still depends heavily on manual workflows compared with other digitised areas of medical imaging.
Morphle’s platform RoboTome automates the slicing of biopsy blocks, offering consistent and high-precision sections. Its companion device, MorphoLens, scans more than 100 slides per hour to enable remote assessments and support higher lab throughput.
The company holds over 80 patents across robotics, optics, embedded engineering and imaging science.
Pratip Mazumdar of Inflexor Ventures said Morphle’s growing traction reflects the rising need to modernise pathology workflows and strengthens its position in deeptech healthcare automation.
